Back to Search
Start Over
Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
- Source :
-
Journal of viral hepatitis [J Viral Hepat] 2023 Sep; Vol. 30 (9), pp. 740-745. Date of Electronic Publication: 2023 Jun 01. - Publication Year :
- 2023
-
Abstract
- Hepatitis C virus (HCV) infection is more prevalent in people living with HIV-AIDS (PLHA) and portends a poorer prognosis. Pharmacokinetic studies suggest the absence of significant interaction between velpatasvir and dolutegravir which has been recently recommended as part of preferred first-line antiretroviral therapy (ART) regimens by WHO. However, clinical data on the use of velpatasvir-based regimen in PLHA taking dolutegavir is lacking. Hence, we aimed to assess the efficacy and safety of sofosbuvir and velpatasvir (SOF + VEL) in HCV and HIV coinfected patients on dolutegravir-based ART. Forty-five consecutive PLHA with HCV coinfection on dolutegravir-based ART were prospectively enrolled. All patients were treated SOF + VEL for 12 weeks. Complete haemogram, liver and renal function tests were assessed at baseline, 4 weeks and at end of treatment. Sustained virological response (SVR) was assessed at 12 weeks after end of treatment. The majority were males (95.5%) with a mean age of 32.8 ± 12.3 years. Cirrhosis was present in 6 (13.3%) patients. All patients completed 12 weeks of therapy with SOF + VEL, but SVR could not be assessed in two patients. Forty-two (97.7%) of the remaining 43 patients attained SVR-12. SVR-12 rate was 97.7% and 93.3% by per protocol and intention to treat analysis, respectively. No grade III/IV adverse events were reported, and there was no worsening of blood counts, liver or renal function test parameters. The pan-genotypic regimen of SOF + VEL is safe and effective in PLHA with HCV coinfection who are on dolutegravir-based ART.<br /> (© 2023 John Wiley & Sons Ltd.)
- Subjects :
- Male
Humans
Young Adult
Adult
Middle Aged
Female
Sofosbuvir adverse effects
Antiviral Agents adverse effects
Hepacivirus genetics
Genotype
Treatment Outcome
Coinfection drug therapy
Hepatitis C, Chronic complications
Hepatitis C, Chronic drug therapy
Hepatitis C drug therapy
HIV Infections complications
HIV Infections drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2893
- Volume :
- 30
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Journal of viral hepatitis
- Publication Type :
- Academic Journal
- Accession number :
- 37260083
- Full Text :
- https://doi.org/10.1111/jvh.13844